Results 11 to 20 of about 2,303 (187)

Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review

Vaccines
Respiratory syncytial virus (RSV) is the primary etiological agent responsible for lower respiratory tract infections (LRTIs) and hospitalizations among infants. Nirsevimab, a novel monoclonal antibody (mAb), offers sustained protection against RSV for a
Fangrui Ding
exaly   +6 more sources

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants [PDF]

New England Journal of Medicine, 2023
The safety of the monoclonal antibody nirsevimab and the effect of nirsevimab on hospitalizations for respiratory syncytial virus (RSV)-associated lower respiratory tract infection when administered in healthy infants are unclear.In a pragmatic trial, we randomly assigned, in a 1:1 ratio, infants who were 12 months of age or younger, had been born at a
Pierre Tissières, Simon B Drysdale, Saul Faust   +2 more
exaly   +10 more sources

Evaluating the Effectiveness of Nirsevimab in Reducing Pediatric RSV Hospitalizations in Spain [PDF]

Vaccines
Background/Objectives: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Nirsevimab has demonstrated to be a promising tool for preventing severe RSV disease.
Sara Jimeno, Adrian Peláez Laderas, Silvina Natalini Martinez   +2 more
exaly   +4 more sources

Parental Acceptance of Nirsevimab for RSV Prevention in Infants Across Two Consecutive Seasons in Emilia-Romagna, Italy [PDF]

Vaccines
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalization in infants. Nirsevimab, a long-acting monoclonal antibody, provides single-dose protection during the RSV season, but the ...
Susanna Esposito, Valentina Fainardi, Maria Elena Capra, Melodie O. Aricò, Angela Lanzoni, Francesco Accomando, Gaia Giorgia Arnesano, Cosimo Neglia, Enrico Valletta, Giacomo Biasucci, Serafina Perrone   +10 more
doaj   +3 more sources

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials

Nature Communications, 2023
Nirsevimab is a monoclonal antibody that binds to the respiratory syncytial virus (RSV) fusion protein. During the Phase 2b (NCT02878330) and MELODY (NCT03979313) clinical trials, infants received one dose of nirsevimab or placebo before their first RSV ...
Bahar Ahani, Kevin M. Tuffy, Anastasia A. Aksyuk, Deidre Wilkins, Michael E. Abram, Ron Dagan, Joseph B. Domachowske, Johnathan D. Guest, Hong Ji, Anna Kushnir, Amanda Leach, Shabir A. Madhi, Vaishali S. Mankad, Eric A. F. Simões, Benjamin Sparklin, Scott D. Speer, Ann Marie Stanley, David E. Tabor, Ulrika Wählby Hamrén, Elizabeth J. Kelly, Tonya Villafana   +20 more
doaj   +2 more sources

Acceptance and impact of Nirsevimab and the RSVpreF vaccine following implementation in Austria [PDF]

Frontiers in Public Health
BackgroundSince summer 2024, passive immunization with nirsevimab (Beyfortus®) has been recommended for all infants in Austria to prevent severe respiratory syncytial virus (RSV) infection.
Jürgen Brunner, Klaus Kapelari, Elisabeth Ralser   +2 more
exaly   +4 more sources

Multicentre study on nirsevimab: Bayesian analysis reveals persisting risk for preterm infants [PDF]

BMJ Paediatrics Open
Objective To evaluate whether the timing and effectiveness of nirsevimab prophylaxis vary by gestational age.Design Retrospective cohort study conducted during two identical epidemic seasons: 2023–2024 (before nirsevimab introduction) and 2024–2025 ...
Federico Marchetti, Enrico Valletta, Gianluca Vergine, Silvia Bloise, Gina Ancora, Enrico Cocchi, Aurora Lorefice, Sara Zannoni, Benedetta Pellegrini, Francesco Saverio Morlupo, Beatrice Scarpellini, Melodie Olivia Loredana Rosa Aricò, Francesco Accomando, Marcello Stella   +13 more
doaj   +2 more sources

Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network [PDF]

Human Vaccines & Immunotherapeutics
Although clinical trials have shown that nirsevimab is safe, post-licensure safety data from routine clinical settings are lacking. This study describes parent-reported health events occurring within seven days of nirsevimab administration.
Marina Viñeta Paramo, Marilou Kiely, Louis Valiquette, Matthew P. Muller, Allison McGeer, Jennifer E. Isenor, Manish Sadarangani, James D. Kellner, Otto G. Vanderkooi, Kimberly Marty, Pascal M. Lavoie, Julie A. Bettinger   +11 more
doaj   +2 more sources

Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials

Pathogens
Background: Nirsevimab is approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season and in children aged ≤24 months who remain vulnerable to severe RSV
Amanda Leach, Robert Kubiak, Manish Shroff   +2 more
exaly   +3 more sources

Real-world effectiveness of nirsevimab against respiratory syncytial virus in pediatric practice: the Piemonitorab study

Italian Journal of Pediatrics
Background Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRTIs) in pediatric populations, resulting in a substantial burden of disease.
Elisa Funiciello, Alessia Spadavecchia, Celeste Cagnazzo, Lorenza Ferrara, Bartolomeo Griglio, Antonino Sottile, Paola Berchialla, Franca Fagioli, on behalf of the Piemonitorab Study Group   +8 more
doaj   +2 more sources